Public Release: 

Researchers begin randomized double-blind trial of airway bypass treatment for emphysema

Broncus Technologies

IMAGE?

IMAGE: The stent is smaller than a pencil's eraser. view more

Credit: Broncus Technologies

Mountain View, CA, May 16, 2007 -- Broncus Technologies, Inc., today announced the start of its EASE (Exhale Airway Stents for Emphysema) Trial to explore an investigational procedure that may offer a new, minimally-invasive treatment option for millions of emphysema sufferers. The study focuses on a procedure called airway bypass that uses drug-eluting stents to reinforce new pathways in the lung for trapped air to escape. This in turn, may relieve severe emphysema symptoms such as shortness of breath.

Leading pulmonologists and thoracic surgeons at medical centers around the world are participating in the EASE Trial to study the safety and effectiveness of airway bypass in people struggling with severe homogenous (or diffuse) emphysema. During the trial, patients are randomized two-to-one to the treatment group (receiving bronchoscopy with placement of the drug-eluting stents) or the control group (undergoing only a bronchoscopy procedure). The trial is underway at 15 leading research institutions with more than 20 patients already randomized. At least 225 patients will be enrolled at up to 45 institutions during the next 12 to 18 months.

Emphysema is a chronic, progressive, and irreversible lung disease characterized by the destruction of lung tissue. The loss of the lungs' natural elasticity and the collapse of airways in the lung combine to make exhalation ineffective, leaving the emphysema sufferer with hyperinflation because they can't get air out of their lungs. Breathing becomes inefficient and patients are always short of breath - making even nominal physical activities difficult. The airway bypass procedure creates new pathways in the lung with the intention of reducing the amount of air trapped in the lungs, thereby helping patients breathe easier.

Emphysema afflicts tens of millions of people worldwide with more than 3 million sufferers in the United States. There is no cure for emphysema.

"The EASE Trial is important because airway bypass may help patients with widespread emphysema whose disease has destroyed tissue throughout the lung. For this patient population, the only current surgical option is lung transplantation," states Joel Cooper, M.D., a pioneer in thoracic surgery, developer of the airway bypass procedure and Chief of the Division of Thoracic Surgery at the University of Pennsylvania Health System. Dr. Cooper is also a co-principal investigator of the EASE Trial and a consultant to Broncus. "By creating new pathways for airflow with the airway bypass procedure, we hope to reduce hyperinflation, improve lung function, and restore the mechanics of breathing."

For patients in the treatment group receiving airway bypass, the physician advances a flexible bronchoscope through the mouth into the airways. There the physician creates new small pathways and places an Exhale® Drug-Eluting Stent - manufactured by Broncus Technologies, Inc. - to allow the trapped air in the lung to escape. The study will determine if patients experience an improvement in dyspnea (shortness of breath) and lung function. The procedure, like many other bronchoscopic procedures, is done under deep sedation or general anesthesia, and the patient returns home the next day.

"With feasibility studies outside of the US already completed, we are very pleased to commence this important pivotal clinical study in collaboration with many of the world's foremost emphysema experts," says Cary Cole, CEO of Broncus.

Ten institutions in the US and five others around the world are currently recruiting patients for the EASE Trial. Involvement in the study will last from approximately 15 months up to 5 years (depending on if the patient is randomized to the control or the treatment group) and include 8 to 16 physician appointments. All study-related medical procedures will be carried out at no charge to the patient and patients will be closely monitored throughout the trial. Participants will also receive at least 14 weeks of pulmonary rehabilitation therapy.

###

If you or someone you know over the age of 35 have been diagnosed with advanced widespread emphysema and no longer smoke (or would be willing to stop smoking two months prior to the study), you may qualify to participate in this study. For more information please call 866-431-3273 or visit www.EASEtrialUS.com.

About Broncus Technologies, Inc.

Broncus Technologies, Inc. is helping people breathe easier by developing bronchoscopic interventions for lung diseases. Founded in 1997, Broncus Technologies has developed the Exhale® Drug-Eluting Stent for use in the airway bypass procedure, a minimally-invasive procedure being investigated to treat emphysema. Airway bypass creates new pathways in the lung for air to escape and may potentially improve the breathing abilities of patients with emphysema. Broncus Technologies is currently conducting the pivotal EASE Trial to evaluate the safety and efficacy of airway bypass in the treatment of advanced widespread emphysema. For more information visit www.broncus.com.

Editors Notes

For more information on the EASE Trial or Broncus Technologies, please contact Meghan Oreste at 617-823-1441 or moreste@comcast.net

For questions about enrolling in the trial call 866-431-3273 or visit www.EASEtrialUS.com

Broncus and Exhale are trademarks of Broncus Technologies, Inc.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.